EGFR and non-small cell lung carcinoma: Part B of the trial enrolled patients with MET-amplified, EGFR mutation-positive NSCLC who had progressed on EGFR-TKI, including a third-generation EGFR-TKI (cohort B1) or an earlier-generation EGFR-TKI with the presence (cohort B3) or absence (cohort B2) of T790M resistance mutation.